IOMAI

IOMAI
Founded1997
FounderGregory Glenn

IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method. This provided a means to stimulate robust immune responses safely as the skin patch-based immunization targeted Langerhans cells in the skin. The patch technology underwent extensive evaluation in the context of a traveler's diarrhea vaccine which entered Phase 3 pivotal trials in 2009. IOMAI was acquired by Intercell in 2008 and the technology was the subject of a development license to GSK in 2009. Dr. Glenn pioneered needle free delivery to the skin and spawned general interest in skin-targeting vaccine technologies, including intradermal delivery and the use of the heat labile toxin as an adjuvant and the adjuvant patch.

See also

References

  • Frech, SA; Dupont, HL; Bourgeois, AL; McKenzie, R; Belkind-Gerson, J; Figueroa, JF; Okhuysen, PC; Guerrero, NH; Martinez-Sandoval, FG; Meléndez-Romero, JH; Jiang, ZD; Asturias, EJ; Halpern, J; Torres, OR; Hoffman, AS; Villar, CP; Kassem, RN; Flyer, DC; Andersen, BH; Kazempour, K; Breisch, SA; Glenn, GM (Jun 2008). "Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial". Lancet. 371 (9629): 2019–25. doi:10.1016/s0140-6736(08)60839-9. PMID 18554712. S2CID 32784525.
  • McKenzie, R; Bourgeois, AL; Frech, SA; Flyer, DC; Bloom, A; Kazempour, K; Glenn, GM (May 2007). "Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study". Vaccine. 25 (18): 3684–91. doi:10.1016/j.vaccine.2007.01.043. PMID 17313998.
  • Glenn, GM; Villar, CP; Flyer, DC; Bourgeois, AL; McKenzie, R; Lavker, RM; Frech, SA (May 2007). "Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum". Infect Immun. 75 (5): 2163–70. doi:10.1128/iai.01740-06. PMC 1865773. PMID 17261601.
  • Glenn, GM; Thomas, DN; Poffenberger, KL; Flyer, DC; Ellingsworth, LR; Andersen, BH; Frech, SA (Dec 2009). "Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch". Vaccine. 27 (Suppl 6): G60–6. doi:10.1016/j.vaccine.2009.10.031. PMID 20006142.
  • Kenney, RT; Frech, SA; Muenz, LR; Villar, CP; Glenn, GM (Nov 2004). "Dose sparing with intradermal injection of influenza vaccine". N Engl J Med. 351 (22): 2295–301. doi:10.1056/nejmoa043540. PMID 15525714.
Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by adding missing information.

Stub icon

This biotechnology article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.